NRM 2021

Online Program Keyword Index

supported by:
Authors
Keywords
Chairs
To search for a specific ID please enter the hash sign followed by the ID number (e.g. #123).
 Total overview
Keyword Contributions
5-ht2a receptor P-WE-6-01 
5ht2c S-02-05 
5xfad P-WE-6-05 
[³h]abp688 P-TH-8-23 
[³h]ucb-j P-WE-6-17 
[¹²⁴i]ibeta P-TU-1-09 
[¹²⁵i]-ippi P-TU-3-10 
[¹²⁵i]iaza P-TU-1-18 
[¹¹c]-(r)-pk11195 P-TU-4-03 
[¹¹c]-ucb-j P-TU-3-15 S-02-04 
[¹¹c]carfentanil P-WE-7-09 
[¹¹c]carfentanil positron emission tomography P-TH-9-09 
[¹¹c]cimbi-36 P-WE-6-01 S-02-05 
[¹¹c]colchicine P-WE-6-06 
[¹¹c]cppc P-TU-1-17 
[¹¹c]dtbz P-TH-8-18 
[¹¹c]hd-800 P-WE-6-06 
[¹¹c]martinostat P-TH-8-01 
[¹¹c]mk-6884 P-WE-6-11 
[¹¹c]nop-1a S-03-10 
[¹¹c]pbr2 P-TU-4-05 
[¹¹c]pbr28 P-TU-4-01 
[¹¹c]raclopride S-02-06 
[¹¹c]ro15-4513 P-TU-4-06 
[¹¹c]ucm1014 P-TU-1-02 
[¹¹c]ucm765 P-TU-1-02 
[¹¹c]verubulin P-WE-6-06 
[¹⁵o] P-WE-5-10 
[¹⁵o]-oxygen P-WE-5-11 
[¹⁵o]-water P-WE-5-06 
[¹⁵o]water P-WE-5-05 
[¹⁸f]-bccp-ef S-02-04 
[¹⁸f]-fdg pet P-WE-5-08 
[¹⁸f]bavarostat P-WE-6-19 
[¹⁸f]ekz-001 P-WE-6-19 
[¹⁸f]fdg brain pet P-TU-3-17 
[¹⁸f]fdg pet P-TU-2-03 
[¹⁸f]fdg suvr P-WE-5-03 
[¹⁸f]fds pet imaging P-TU-1-12 
[¹⁸f]feppa P-TU-4-08 
[¹⁸f]flortaucipir P-TH-8-14 
[¹⁸f]flotaza P-TU-1-09 
[¹⁸f]fluoroagomelatine P-TU-1-02 
[¹⁸f]fpeb P-TU-3-18 
[¹⁸f]nos S-02-10 
[¹⁸f]synvest-1 P-WE-6-09 
a2a receptor P-TU-1-13 
acetylcholine receptors P-WE-6-08 
addiction P-TH-9-05 
adenosine a1 receptor P-WE-7-05 
adenosine receptor P-TU-1-13 P-WE-7-04 
adrenergic receptor P-WE-7-11 
aging P-TU-1-15 P-WE-7-10 
alcohol-use disorder S-03-10 
alpha-synuclein P-WE-6-02 P-WE-6-10 S-01-02 
alpha7 P-WE-6-08 
alzheimer's disease P-TH-10-02 P-TH-10-05 P-TH-10-07 P-TH-8-04 P-TH-8-05 P-TH-8-14 P-TH-8-16 P-TH-8-17 P-TH-8-19 P-TH-8-20 P-TH-8-21 P-TH-8-22 P-TH-8-24 P-TH-8-25 P-TU-1-03 P-TU-1-04 P-TU-1-05 P-TU-1-09 P-TU-1-10 P-TU-1-11 P-TU-1-18 P-TU-1-22 P-TU-3-02 P-TU-3-05 P-TU-3-09 P-TU-3-10 P-TU-3-14 P-TU-3-16 P-WE-6-05 P-WE-7-08 S-01-03 S-01-07 S-03-01 S-03-02 S-03-03 S-03-04 S-03-05 
amnestic mci P-TU-3-05 
amphetamine S-02-06 
amplitude of low frequency fluctutations S-02-04 
amyloid P-TH-10-07 P-TH-8-03 P-TH-8-05 P-TH-8-20 P-TH-8-21 P-TH-8-25 P-TH-8-26 P-TU-1-05 P-TU-1-09 P-TU-1-18 P-TU-4-09 P-WE-6-04 P-WE-6-05 S-01-03 S-01-05 S-03-01 S-03-02 
amyotrophic lateral sclerosis P-TH-8-02 
animal model S-02-01 
anosmia P-TH-8-19 
antidepressant treatment response prediction P-TH-9-13 
apoe S-03-03 
arterial spin labeling P-WE-5-09 P-WE-5-10 
astrocytes P-TU-1-05 
asymmetry P-TU-4-03 
atlas P-WE-7-01 P-WE-7-07 
atp-binding cassette P-TU-1-06 
autism P-TH-9-11 
autism spectrum disorder P-TH-9-12 S-03-08 
autism spectrum disorder (asd) P-TH-8-08 
autoradiography P-TH-8-23 P-TU-3-06 P-TU-3-18 P-TU-4-04 P-WE-6-17 P-WE-7-01 P-WE-7-08 S-01-02 
basal ganglia encephalitis P-WE-6-07 
bayes factor P-TU-3-21 
bayesian P-TU-2-02 P-TU-2-05 
bayesian modeling P-TU-3-04 
behavioral challenge P-TU-2-04 
behavioral psychology P-TH-8-08 
between-subject variance P-TU-4-07 
binding P-TU-4-03 
binding potential P-TU-3-08 P-TU-3-12 
binding potential (bpnd) P-TU-4-08 
biodistribution P-TU-1-16 
biomarker P-TH-10-05 S-02-01 
biomarkers P-TH-8-20 S-03-01 
blood biomarker P-TH-10-02 
blood brain barrier P-TU-1-12 S-03-09 
blood-free pet quantification P-TU-2-01 
bmi P-WE-7-10 
bolus-infusion P-WE-6-01 
braak stages P-TU-3-16 
brain P-WE-7-05 
brain development P-WE-6-18 
brain mapping P-TU-3-13 
brain pet P-TU-3-08 S-01-08 
caffeine P-WE-7-04 
camp P-TU-1-08 
carbon-11 P-TU-1-07 
carfentanil P-WE-7-07 
cbd P-TU-1-11 
centiloids P-TH-8-26 
cerebral amyloid angiopathy S-01-05 
cerebral blood flow P-TH-8-03 P-TH-8-14 P-WE-5-01 P-WE-5-06 S-01-03 S-03-02 
cerebral cortex P-TU-3-16 
cerebral metabolism P-WE-5-11 
cerebrovascular disease S-01-10 
cerebrovascular reactivity S-01-10 
chemogenetics S-01-04 
childhood trauma P-TH-9-10 
choroid plexus P-TH-8-09 S-03-09 
chronic pain P-TH-10-06 
chronic traumatic encephalopathy P-TH-8-11 
clearing agent P-WE-6-04 
click-reaction P-WE-6-04 
clinical assessment P-TH-8-13 
clinical trials P-TH-8-08 
cmrglu P-TU-2-03 
cmro2 P-WE-5-11 
cocaine P-WE-6-17 
cognition P-TH-8-14 P-TU-3-07 
cognitive decline P-TH-10-05 P-TU-4-09 
cognitive reserve P-TH-10-08 
compartmental modeling P-TU-2-05 
compartmental modelling P-WE-7-11 
connectivity P-TH-8-05 P-TH-8-16 
cortical thickness P-TH-8-25 
covid P-TH-10-07 
covid-19 P-TH-10-03 
cox-2 P-TU-1-23 
crispr/cas9 S-02-03 
csf P-TH-10-04 P-TH-8-22 
csf1r P-TU-1-04 
cyclooxygenase 1 P-TU-1-20 
cyclooxygenase 2 P-TU-1-20 
cyclooxygenase-1 and -2 P-TU-1-01 
cyclooxygenase-2 P-TU-1-14 
d3 receptors P-TU-1-21 
data harmonization P-TU-3-08 
data-driven methods S-02-08 
datscans P-TU-3-04 
dementia P-TH-8-17 P-WE-5-10 
demyelination P-WE-6-14 
denoising S-02-08 
depression P-TH-9-02 P-WE-5-02 S-03-09 
deschloroclozapine (dcz) S-01-11 
designer receptor exclusively activated by designer drugs (dreadd) S-01-11 
diprenorphine P-WE-7-07 
direct-4d reconstruction P-TU-4-07 
disease progression S-03-04 
disease progression models P-TU-3-04 
displacement P-WE-6-01 
docosahexaenoic acid P-TU-4-01 
dopamine P-TH-9-05 P-TH-9-07 P-TU-1-21 P-TU-2-04 P-TU-3-19 P-WE-7-03 S-02-06 
dopamine d2-receptor P-TH-9-15 
dopamine release P-TH-9-06 S-02-08 
dopamine synthesis P-TH-9-06 S-02-07 
dopamine transporter P-TH-8-15 
dopaminergic degeneration P-WE-6-02 
dopaminergic system P-TU-3-01 P-WE-7-02 
dorsal attention network P-WE-6-16 
dosimetry P-TU-1-16 
down syndrome P-TH-8-26 
dreadds S-01-04 
drug-drug interaction P-TU-1-06 
dtbz P-TH-8-06 
dti P-TH-8-02 P-TH-9-15 
dynamic (dvr/bpnd) P-TU-3-14 
dynamic functional connectivity P-WE-5-08 
dynamic pet P-TU-4-06 
dynamics P-TU-3-07 
early detection P-TU-3-09 
early life stress P-TH-9-07 
early stopping P-TU-3-21 
ec50 S-01-08 
endocannabinoid system S-02-09 
enzyme P-TU-1-19 
epigenetics S-03-08 
epilepsy P-TH-8-07 
er176 P-WE-6-07 
executive function P-WE-6-16 
externalizing traits P-TH-9-07 
extracerebral signal S-01-07 
f18-cpfpx P-WE-7-05 
fatty acid hydrolase S-02-09 
fazin3 P-TU-1-22 
fdg P-TH-9-13 P-WE-5-01 P-WE-5-02 
fdg-pet P-TU-3-05 
fdopa pet S-03-06 
fear P-WE-7-03 
first-in-human P-TU-1-17 
fluorine-18 P-TU-1-13 P-TU-3-02 
fmri S-02-04 
focused ultrasound P-TU-1-12 
fpeb P-TH-9-02 
free water P-TH-8-24 
frontal cortex P-TU-3-12 
frontotemporal dementia P-TU-1-15 
ftc146 S-01-01 
fully quantitative P-TH-9-13 
function P-TU-3-07 
functional connectivity P-WE-5-04 S-02-03 
functional mri P-TH-8-03 P-WE-5-09 
functional pet P-WE-5-07 P-WE-5-09 S-02-07 
gaba P-WE-7-01 
gender P-WE-7-05 
gene editing S-02-03 
gene expression P-TU-3-06 
genes S-02-03 
genetics S-03-05 
geometric transfer matrix P-TU-2-05 
glial activation P-TH-10-04 
glial cells P-TH-10-06 
glioma P-WE-5-05 
glucose metabolism P-WE-5-01 P-WE-5-04 
glun2b subunit P-TU-1-16 
glutamate P-TH-9-06 P-TH-9-16 
glycogen synthase kinase-3 P-TU-1-01 
graph theory P-WE-5-08 
gray matter volume P-TU-3-12 
grey matter volume P-TH-9-06 
hdac S-03-08 
hdac6 P-WE-6-19 
healthy P-TH-10-03 
healthy ageing P-WE-6-09 
heterogeneity P-WE-5-05 
hippocampus P-TH-8-23 
histone deacetylases P-TH-8-01 
ht1a receptors P-TU-1-21 
human P-TH-9-04 
human embryonic stem cells P-WE-6-12 
human hippocampus P-WE-7-08 
huntington's disease S-02-01 
i-124 P-WE-6-05 
idif P-TU-2-03 P-TU-4-05 
image analysis P-TU-3-10 P-TU-4-02 
image derived input function P-TU-2-05 
image quality P-TU-3-17 
image-derived input function P-WE-5-06 
image-derived input function (idif) P-TU-4-08 
imaging biomarker P-TH-10-02 
immune activation P-TH-9-14 
immune system P-TH-8-20 
independent component analysis P-TU-3-05 
inflammation P-TH-10-06 P-TU-1-20 
injected radioactivity P-TU-3-21 
inter-scanner P-TU-3-08 
internalization S-02-06 
ippi tau P-WE-7-08 
irreversible kinetics P-TU-2-01 
keynote KN-02-01 KN-03-01 
kinetic modeling P-TU-2-01 P-TU-2-04 P-TU-3-03 P-TU-3-18 P-TU-3-19 
kinetic modelling P-WE-6-09 
kinetic models S-01-11 
lassen plot S-01-08 
lateral ventricles P-TH-8-09 
lateralization P-TH-8-10 
lesions P-TH-8-01 
lewy bodies P-TU-4-02 
limbic system P-TH-9-12 
lipopolysaccharide P-WE-6-03 
longitudinal P-TU-3-15 
longitudinal [¹⁸f]flortaucipir pet P-TU-3-14 
m4 machr P-WE-6-11 
macrophage colony stimulating factor 1 receptor P-TU-1-17 
magl P-TU-1-19 
major depressive disorder P-TH-9-10 P-TH-9-13 
mao-a S-03-01 
mapping P-WE-6-16 
mdd P-TU-1-08 
medial temporal lobe P-TH-8-10 
melatonin receptors P-TU-1-02 
membrane transporter P-TU-1-06 
mental health P-TH-9-07 
mesial temporal lobe epilepsy P-TH-8-23 
metabolic connectivity mapping P-WE-5-04 
metabolism P-TH-9-10 P-WE-5-07 
metabotropic glutamate receptor 5 (mglur5) P-WE-6-15 
mglur5 P-TH-8-23 P-TH-9-02 P-TU-3-02 
mgur5 P-TH-9-04 
mhtt S-02-01 
mice P-WE-6-09 
microdialysis P-TH-9-16 
microglia P-TH-8-19 P-TU-1-03 P-TU-1-04 P-TU-1-17 P-TU-1-23 P-WE-6-07 
microparameters P-TU-2-03 
microstructure P-TH-8-24 
microtubules P-WE-6-06 
mild cognitive impairment P-TU-1-05 
mild traumatic brain injury P-TH-8-11 S-02-09 
minipigs P-WE-6-12 P-WE-6-13 
mk-6240 S-01-07 
mk2640 P-TH-8-22 
modeling P-TU-1-19 
modelling P-WE-7-06 
molecular connectivity P-TU-4-06 
molecular imaging S-02-02 
money P-TU-3-21 
monkey S-01-04 
monoamine oxidase P-TU-4-02 
monoamine oxidase a P-TU-1-22 
monoamine oxidase b P-WE-6-03 
morphine S-03-07 
mouse imaging P-TU-1-01 
mri P-TH-9-10 P-WE-5-10 
mrna P-TH-10-01 P-WE-7-01 
mrs P-TH-10-03 
mu opioid receptor P-TH-9-09 
mu-opioid receptor P-WE-7-09 
multi-modal S-03-04 
multi-site pet P-TU-3-03 
multi-tracer pet P-TH-8-12 
multicenter collaboration P-TH-9-14 
multimodal analysis P-TH-8-03 
multimodal imaging P-TH-10-01 
multimodal neuroimaging P-TH-9-08 S-02-04 
multiple regression modelling P-WE-5-03 
multiple sclerosis P-TH-8-01 
multiple system atrophy S-01-02 
myelin P-TU-3-13 
n-methyl-d-aspartate P-TH-9-16 
net influx rate P-TU-2-01 
network P-TH-8-05 
neurobiology P-TU-3-13 
neurodegeneration P-TH-10-05 P-TH-8-09 P-TU-1-13 S-03-04 
neurodevelopmental disabilities P-TH-8-08 
neuroepigenetics P-TH-8-01 
neuroimaging P-TH-9-16 P-TU-3-09 P-WE-6-11 S-02-02 
neuroimmune system S-03-07 
neuroinflamation P-TH-8-02 
neuroinflammation P-TH-10-03 P-TH-10-07 P-TH-8-16 P-TH-8-25 P-TU-1-10 P-TU-1-14 P-TU-1-23 P-WE-6-03 S-02-10 S-03-03 S-03-09 
neuronal plasticity-related proteins P-TH-9-01 
neuropathic P-TH-10-06 
neuropharmacology P-TU-1-06 
neuroplasticity P-WE-5-04 
neuropsychiatric disorders P-TU-1-16 
neuropsychologytau P-TH-8-13 
neuroreceptor template P-WE-7-06 
neurotransmitter release P-WE-7-03 
neurotransmitters P-TU-4-04 
neutrophils P-TH-8-20 
nhp P-WE-6-11 
nifene P-WE-7-08 
nmda receptor P-TU-1-16 
nondisplaceable binding potential P-TH-9-12 
nonverbal memory P-TH-8-10 
norepinephrine P-WE-7-10 
norepinephrine transporter P-TH-9-01 
novel pattern analysis P-TU-3-01 P-WE-7-02 
nr2b-sme S-01-01 
nr2b/nmda receptor S-01-01 
nucleus accumbens P-TH-9-09 
obesity P-WE-5-01 
occupancy S-01-08 
olfaction P-TH-8-19 
oncology P-TU-1-01 
opioid P-TH-9-05 
opioid receptor P-WE-7-07 
opioid use disorder S-03-07 
optimization P-TU-3-17 
optogenetics S-01-09 
oxidative stress P-WE-6-10 
oxygenation S-01-10 
p-tau P-TH-8-22 
p-tau biomarkers P-TH-10-02 
pam P-WE-6-11 
pandas P-WE-6-07 
parametric-molar P-TU-4-07 
parkinson's disease P-TH-8-15 P-TU-3-01 P-WE-6-10 P-WE-6-12 
parkinson’s disease P-TH-8-06 P-TH-8-12 P-TH-8-18 P-TU-1-22 P-TU-3-04 P-TU-4-02 P-TU-4-09 P-WE-7-02 S-01-02 S-02-10 
partial volume correction P-TU-2-05 P-TU-3-03 
pbif P-TU-4-05 
pd rodent model P-WE-6-02 
pde4b P-TU-1-08 
perfusion P-WE-5-05 S-01-10 
pet P-TH-9-01 P-WE-7-11 
pet [¹⁸f]flortaucipir P-TH-8-11 
pet imaging P-TU-1-01 P-TU-3-02 P-WE-6-02 P-WE-6-12 P-WE-7-10 S-01-05 S-02-01 
pet reporter systems S-02-02 
pet tracer evaluation S-01-02 
pet-bids P-TU-3-11 
pet-imaging P-TH-8-21 
pet-mr P-TH-8-02 
pet-mri P-WE-5-07 S-03-08 
pet/ct P-WE-6-05 S-02-10 
pet/ct studies P-TU-1-09 
pet/fmri S-02-03 
pet/mr P-WE-5-01 P-WE-5-09 
pet/mri P-TH-8-03 P-TU-2-04 P-TU-3-19 P-WE-5-06 P-WE-5-11 S-01-10 S-02-06 
pf-06445974 P-TU-1-08 
pharmacokinetic P-TU-1-06 P-TU-1-12 P-TU-2-02 P-TU-3-13 
photoacoustic P-TH-9-16 
pick's disease P-TU-1-11 
piglets P-WE-6-08 
polygenic score P-TU-3-12 
population variability P-WE-7-06 
positron emission tomography (pet) P-TH-8-08 
positron-emission tomography P-TU-1-14 
post-traumatic stress disorder P-TH-9-03 
posttraumatic stress disorder P-WE-6-15 S-02-09 
pre-clinical imaging P-TU-1-23 P-WE-6-18 
pre-targeting P-WE-6-04 
precision medicine S-03-06 
preclinical P-WE-6-13 
preclinical alzheimer's P-WE-6-16 
principal component analysis S-02-08 
propagation P-TU-3-16 
proteome P-TH-10-01 
proteomics P-WE-6-15 
psams S-01-04 
psychiatry P-TH-9-07 
psychosis P-TH-9-14 S-03-06 
quantification P-TU-3-14 P-TU-3-17 S-01-03 
qupath P-TU-3-10 P-TU-4-02 
r1 S-03-02 
raclopride P-WE-7-03 
radiochemistry P-TU-1-07 
reactive oxygen species P-WE-6-10 
receptor desensitization P-WE-7-09 
receptor trafficking P-WE-7-09 
receptors P-TU-4-04 
reconstruction P-TU-3-17 P-TU-4-04 
reference region P-TU-3-18 
refractory P-TH-8-07 
rejection sensitivity P-TH-9-09 
reliability P-WE-7-11 
rem sleep behaviour disorder P-TH-8-18 
resting state P-WE-5-03 
resting state brain networks P-WE-5-08 
reward circuitry S-03-07 
reward processing S-02-07 
rheumatoid arthritis P-TU-1-20 
ripk1 P-TU-1-03 P-TU-1-10 
rodent models P-WE-6-15 
rostrace P-WE-6-10 
scanning window P-TH-8-06 
schizophrenia P-TH-9-08 P-TH-9-14 P-TH-9-15 
sequential testning P-TU-3-21 
serotonin S-02-05 
serotonin receptor P-TU-3-12 
sigma receptor S-01-01 
signal standardization P-TU-4-06 
simulations S-01-08 
simultaneous estimation (sime) P-TU-4-08 
simultaneous estimation (sime) of the arterial input function P-TH-9-13 
simultaneous fpet/fmri S-01-09 
simultaneous pet/fmri P-WE-5-03 P-WE-5-08 
sleep P-WE-5-07 
small vessel disease P-TH-8-24 
social isolation P-TH-9-01 
source-to-target modeling P-TU-2-01 
spatial patterns P-TH-8-12 
spatio-temporal patterns P-TU-3-01 P-WE-7-02 
spectral analysis S-01-07 
static (suvr) P-TU-3-14 
statistics P-TU-2-02 
stress-enhanced fear learning (sefl) P-WE-6-15 
structure P-TU-3-07 
subjective cognitive decline S-03-02 
sucrose P-TH-9-05 
sucrose-consumption P-WE-6-13 
suicide P-TH-9-04 
sulfonylurea receptor 1 P-TU-1-07 
support vector machine P-TH-8-22 
suvr bias S-01-03 
sv2a P-TH-9-02 P-TU-3-15 P-TU-3-20 P-TU-4-07 P-WE-6-13 P-WE-6-17 
synapses P-TU-3-20 
synaptic activity P-TH-8-04 
synaptic density P-TH-8-04 P-TH-8-15 P-TH-9-11 P-TU-1-15 P-TU-3-15 P-WE-6-17 P-WE-6-18 
synaptic dysfunction P-TH-10-04 
target engagement P-TH-9-12 
target occupancy P-WE-6-19 
tau P-TH-10-04 P-TH-10-07 P-TH-8-04 P-TH-8-05 P-TH-8-11 P-TH-8-13 P-TH-8-14 P-TH-8-16 P-TH-8-17 P-TH-8-21 P-TH-8-25 P-TH-8-27 P-TU-1-18 P-TU-3-10 P-TU-3-16 P-WE-6-16 S-03-01 S-03-03 S-03-05 
tau pet P-TH-8-10 S-01-07 
tau proteins P-TH-8-19 
tauopathies P-TU-1-11 
tauopathy P-TU-3-09 
test-retest P-TU-3-08 P-TU-3-15 
test-retest reliability P-WE-5-09 
thalamus P-TH-9-15 
tms P-WE-5-02 
tracer development S-01-05 
transcriptome P-TH-10-01 
trauma P-TH-9-04 
traumatic brain injury P-TH-8-09 P-WE-6-14 
treatment response S-03-06 
tspo P-TH-9-03 P-TH-9-14 P-TU-4-01 P-TU-4-03 P-WE-6-03 S-03-07 
twins S-03-05 
two-tissue compartment modelling P-TU-4-08 
ucb-j P-TH-9-02 P-TH-9-11 P-TU-3-20 P-WE-6-13 
upper motor neuron P-TH-8-02 
vagus nerve stimulation P-WE-6-08 
variational bayesian P-TU-2-03 
vascular risk factor P-TH-10-05 
vasculature P-TU-3-13 
vbm P-TH-9-06 
verbal fluency P-TH-8-21 
verbal memory P-TH-8-13 
visual memory P-TH-8-13 
vmat2 P-TH-8-18 
voxel-based analysis P-TU-3-05 
voxelwise analysis S-02-08 
white matter P-TH-8-24 
within-scan challenges P-WE-6-01 
within-subject variance P-TU-4-07 
yohimbine P-WE-7-11